The Gilead Leadership Team in Italy
María Río has had a vast career in the pharmaceutical industry. She has held management positions, both nationally and internationally, in various companies such as Eli Lilly, Janssen and GSK. At GSK, she served as Vice-President and Director of the Centre of Excellence for Urology for Europe, Asia-Pacific, Japan, and emerging markets, overseeing commercial strategies, R&D programs, and market access programs for Urology products.
In 2012 Río joined Gilead Sciences Spain as General Manager and in 2017 she was appointed Vice-President.
In 2020 she received the Award for Most Innovative Business Leader from "Cinco Días", a business newspaper, at its Business Innovation Awards. In 2021, "Redacción Medica", a healthcare newspaper, chose her as the Best Company Executive in its annual "Sanitarias" Health Awards.
She holds a degree in Pharmacy from the University of Santiago de Compostela and an MBA from IESE in Barcelona. Río is currently a Member of the Board of Directors of Amcham (American Chamber of Commerce in Spain) and the Círculo de Empresarios.
Giovanni Alquati began his career in the industrial chemical sector at Montedison, and then moved to the pharmaceutical sector in the Schering-Plough’s branch, initially in Marketing and then switching to Management Control and then to the Parent Company’s International Finance team. Back in Italy, he assumed the position of Finance Director, Director of Primary Care and finally Director of Business Operations. He then continued at Amgen, where he held the position of Director of Sales & Marketing Effectiveness. He joined Gilead in October 2010 as Director of Commercial Operations and then, in September 2013, began focusing on Market Access as a Function Manager.
Giovanni graduated with honors in Chemical Engineering from the Politecnico di Milano, Alquati then obtained a Masters in Business Administration from SDA Bocconi in Milan.
Arcidiacono gained twenty years of experience in the pharmaceutical sector working at the national and international level in various companies, including Schering-Plough, Roche and Novartis, mainly dealing with Immunology, CNS and Oncology.
In October 2018, Massimiliano joined Gilead UK with the role of Commercial Director EMEA for the launch of a new molecule in the rheumatology area. Since 2020 Massimiliano has been working at Gilead Italy, where he has held the role of Senior Director, first for the IBD Business Unit, and then for the onco-hematology area.
Arcidiacono obtained a degree in Agriculture from the Università di Milano in 2001, and afterwards a Masters in Marketing Management from ISTUD.
Michele Calò started his career in the pharmaceutical sector in the Menarini group, continuing then in Pharmacia & Upjhon, where he held roles of increasing responsibility within the commercial organization, including those of Sales Director, first in the CNS Area and then in the Inflammation Area. In 2002, he moved first to Simesa and then to AstraZeneca and Simesa, where he led the entire Sales Primary Care organization by launching several blockbuster products. Since May 2008 he has been working in Gilead Italy, where he held various marketing roles, including that of Business Unit Director in the Liver and ANF areas and, currently, that of Senior Director, Commercial Operations.
He has a degree in Animal Production Sciences at the Veterinary Faculty of the Università Statale di Milano.
Filippo Cerruti began his career as a criminal lawyer in Genoa. He then continued as a corporate lawyer, working in-house first at Camuzzi SpA, an Italian holding company, and then in Avon Srl, the Italian branch of the American cosmetics corporation. Successively, Cerruti moved to the pharmaceutical sector joining Gentium SpA, a small Italian biotech, where, as head of the Legal Department, he contributed to the success of the transition that followed the acquisition of the company by Jazz Pharmaceuticals. Cerruti then continued his career at Amgen, where he held roles of increasing responsibility, until he took on the position of Legal Director for Italy and Greece. He has been with Gilead since 2019, where he holds the position of Senior Director Legal & Compliance.
Cerruti graduated in Law from the Università Statale di Milano and then obtained the title of Attorney-at-Law in Genoa.
Rosalba Gregorini started her career in the pharmaceutical sector at SmithKline Beecham, then continued at Merck Sharp & Dohme, at the FDA approved production site, where she held various roles of increasing responsibility, including those of Process Scientist and Regulatory & Quality Documentation Manager. She then gained experience in the headquarters regulatory area, assuming the position of Corporate Regulatory Affairs and Compliance Manager in Chiesi. At Celgene, she held the role of Regulatory Affairs & Quality Associate Director. Since February 2021, she has been Senior Director, Regulatory Affairs in Gilead Sciences Italy.
Gregorini graduated in Chemistry and Pharmaceutical Technologies at the Università di Pavia, and then obtained a specialization in Hospital Pharmacy at the Università di Milano, followed by a II level Masters in Regulatory Affairs at the Università di Pavia.
Bernard Kilbane began his professional journey at Johnson & Johnson Italia, gaining experience in several marketing and sales roles of increasing responsibility, both in Italy and at EMEA level. In 2012 he joined Bristol-Myers Squibb, where he became Business Unit Director for Virology, working in the HIV & hepatitis therapeutic areas. In 2017, he joined Zambon Pharma to assume the role of Chief Marketing Officer, leading the product strategy globally, as well as the pipeline management, through Business Development and R&D.
Kilbane has a degree in Electronic Engineering from the University of Limerick, in Ireland, and an MBA from SDA Bocconi in Milan.
Vesselina Kirilova began her career in the pharmaceutical sector at Baxter, then continued with Serono and Schering AG. She joined Gilead Sciences Italy in 2010, holding roles of increasing responsibility in marketing before moving on to lead the Onco-Hema Business Unit. Since February 2020, she is Business Unit Director Cell Therapy with responsibility for the team and Kite’s portfolio in Italy.
Kirilova graduated in Business Administration and Journalism/Mass Communications at the American University in Bulgaria (AUBG), and then obtained a Masters in International Healthcare Management, Economics and Policy (MIHMEP) at SDA Bocconi in Milan.
Cristina Le Grazie began her career first at Basf Pharma as Medical Advisor and then at Schering Plough as Medical Lead of the Primary care and Cardiovascular area. She joined Gilead Italy in 2010 as Senior Medical Manager for hepatitis B and was then promoted in 2011 to Medical Director. She is a member of the Italian Leadership Team, Country Medical Directors team, Compliance Committee and Project Review Board. She supervises and has leadership responsibilities for the Italian Medical Affairs team.
She graduated summa cum laude in Medicine at Università degli Studi di Milan, and then obtained with full marks a post-doctoral degree in Hematology and another one in Clinical Pharmacology.
Silvia Miliani started her professional career first working in GE Healthcare as HR Specialist for Italy, Israel, Greece and Turkey and then, in 2006, moved to PerkinElmer, a leading company in the scientific instrumentation sector, where she gained dual experience managing Italy, Spain and Poland as HR Manager and working as HR Leader Europe in partnership with the Sales, Finance and Customer Care functions. Since January 2012, she has been working at Gilead as Senior Director HR for Italy.
She graduated in Political Science from the Università Statale di Milano, and then obtained a post-graduate specialization in HR.
Marco Moriero began his professional path at the Walgreens Boots Alliance group, in 1999. He moved to Milan two years later to continue his growth in the Healthcare division of General Electric. In 2005, he joined the Medtronic group, where he held roles of increasing responsibility at national and international level in the Finance sector. He moved to Zurich in 2009 to take on the role of Divisional Controller EMEA, Vascular Therapies, and then that of Sr. Director Europe, Advance Surgical Technologies. He returned to Italy in 2016 to assume the position of CFO Italy, and subsequently that of Director, Restorative Therapies Group, with Commercial and Marketing responsibilities for five Business Units. Since May 2021 he has been Executive Finance Director of Gilead Sciences Italy.
Moriero has a degree in Economics from the Università di Pisa and a Masters in Business Administration from the IE Business School of Madrid.
Valentina Raiola began her career in the pharmaceutical sector as a pharmaceutical sales representative at Merck Sharp & Dohme Italia, then moving on to Bristol Myers Squibb, where she held several roles of increasing responsibility, first in Marketing and then in Market Access. In 2014 she returned to Merck Sharpe & Dohme to cover the role of Marketing Director, Infectious Disease, and after 2 years she was entrusted with the direction of the virology franchise. In 2018 she joined Gilead as Business Unit Director, Liver and in 2021 she moved to the Oncology unit.
She graduated in Pharmacy at the Università Federico II di Napoli, and then obtained a Masters in Business Administration from LUISS Guido Carli.
A member of the Journalists’ Association since 2007, Gemma Saccomanni began her career in communication in Public Relations agencies, with corporate and consumer customer responsibilities and as Healthcare Practice Leader in multinational agencies. She then continued her professional path first in Eli Lilly and later in Amgen, before joining Gilead in 2015. Throughout her career, she has built experience in institutional communications, crisis management, executive communications and management of multi-stakeholder communication campaigns, with a responsibility for relations with Patient Organizations and NGOs.
Michelangelo Simonelli’s career began in marketing and sales at Merck, following a move to Bristol-Meyers Squibb where he was a Business Unit Director and then Abbott Laboratories where he was a Business Unit Director. He joined Gilead in 2014 as a Business Unit Director and has been Senior Director, Government Affairs, Italy since 2017.
Simonelli has a degree in Chemistry and Pharmaceutical Technologies from Sapienza Universita di Roma.